
News|Articles|November 5, 2014
Vaccine Strategies in Follicular Lymphoma
Author(s)Joshua Brody, MD
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma.
Advertisement
Clinical Pearls
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma. Brody presented on this topic at the 2014 Chemotherapy Foundation Symposium.
- First generations of lymphoma vaccines looked promising, but were not efficacious enough to become standard therapies.
- New lymphoma vaccines take a more holistic perspective targeting any tumor-specific or tumor-associated antigens.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
5


























